Contents
Vol 6, Issue 232
Contents
Editorial
- Active Skepticism: Beyond the IOM’s CTSA Report
U.S. national networks must set achievable modest goals and match them with reasonable resources in order to facilitate translational medicine projects.
Focus
- Manufacturing Challenges in Regenerative Medicine
Along with scientific and regulatory issues, the translation of cell and tissue therapies in the routine clinical practice needs to address standardization and cost-effectiveness through the definition of suitable manufacturing paradigms.
Research Articles
- FibronectinEDA Promotes Chronic Cutaneous Fibrosis Through Toll-Like Receptor Signaling
FibronectinEDA is an endogenous TLR4 ligand in scleroderma.
- Induction of Antigen-Specific Immunity with a Vaccine Targeting NY-ESO-1 to the Dendritic Cell Receptor DEC-205
Dendritic cell targeting safely leads to integrated humoral and cellular immunity when combined with TLR agonists in cancer patients.
- An Orally Available, Small-Molecule Polymerase Inhibitor Shows Efficacy Against a Lethal Morbillivirus Infection in a Large Animal Model
An orally available, shelf-stable pan-morbillivirus inhibitor targeting a viral polymerase effectively treats ferrets infected with a lethal dose of a measles-like virus.
Editors' Choice
- "Antigenomic" RNA as a Therapeutic Tool for Mitochondrial Diseases
Targeting point mutations in mtDNA with antigenomic RNA restores normal mitochondrial function.
- Inflammatory Web Catches Vessels
A newly discovered candidate gene for a devastating pediatric vascular disease encodes an aberrant form of adenosine deaminase 2, which creates an inflammatory environment.
- Matrix in the Driver’s Seat
The extracellular matrix can alter fibroblasts and affect the fibrogenic process that leads to disease.
- Stopping Seizures After Brain Injury
The FDA-approved antihypertensive agent losartan prevents injury-induced epilepsy in rats by blocking pathogenic TGF-β signaling.
